Zura Bio Limited (ZURA) makes the list of 12 hot penny stocks with strong 3-month performance and upside potential. Guggenheim reiterates a “Buy” rating on ZURA with a $15 price target. The company reported Q3 2025 results, closing the quarter with $139 million in cash, enough to fund operations into 2027.

Zura Bio Limited (ZURA) is focusing on two Phase 2 tibulizumab studies for autoimmune and inflammatory diseases. TibuSHIELD targets hidradenitis suppurativa, with expected data in Q3 2026, while TibuSURE targets systemic sclerosis with data anticipated in Q4 2026. Management emphasizes patient enrollment and competitive trial recruitment dynamics.

While Zura Bio Limited (ZURA) shows investment potential, some believe AI stocks offer greater upside with less risk. For a potentially undervalued AI stock benefiting from tariffs and the onshoring trend, explore the best short-term AI stock. Check out the 12 best commodity stocks and 10 best crypto-related stocks for more investment ideas.

Read more at Yahoo Finance: Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress